Cardarine (GW-501516) vs Ostarine (MK-2866 / Enobosarm)

Mechanism

Cardarine is a selective peroxisome proliferator-activated receptor delta (PPARd) agonist, not a SARM (it does not bind the androgen receptor). PPARd activation in skeletal muscle upregulates genes for fatty acid oxidation (CPT1B, PDK4, ACOX1), shifting fuel substrate from glycolysis toward beta-oxidation, effectively increasing endurance capacity and fat utilization. It increases oxidative type I (slow-twitch) muscle fiber proportion, enhances mitochondrial biogenesis via PGC-1a coactivation, reduces circulating triglycerides and LDL, and increases HDL cholesterol. PPARd activation also reduces macrophage-mediated inflammation through NF-kB suppression.

Standard Dosing

Research indicates 10-20 mg daily orally for 8-12 weeks. Clinical trials (metabolic syndrome) used 2.5-10 mg/day.

Timing

Once daily, 1-2 hours before exercise for acute endurance benefit. Half-life approximately 16-24 hours. Consistent daily dosing.

Cycle Duration

8-12 week cycles. No HPG suppression, so PCT is not required. However, long-term safety is unknown and cycling is prudent.

Side Effects

• CANCER RISK: Accelerated tumor development in multiple organs observed in 2-year rodent study at all doses tested
• Headache
• Nausea
• Diarrhea
• Potential liver effects at high doses

Contraindications

• Active or history of cancer (CRITICAL — see notes on carcinogenicity)
• Pregnancy and breastfeeding
• Individuals under 21
• Liver disease

Best Stacking Partners

Mechanism

Ostarine (enobosarm/GTx-024) is a nonsteroidal selective androgen receptor modulator that binds the androgen receptor with high affinity, inducing a conformational change that recruits coactivator proteins preferentially in muscle and bone tissue over prostate and seminal vesicles. This tissue selectivity arises from differential AR cofactor recruitment and 5-alpha reductase metabolism. Ostarine promotes lean body mass by activating AR-mediated transcription of anabolic genes (MYC, IGF-1) in myocytes while minimizing androgenic effects in reproductive tissues. It has demonstrated dose-dependent increases in lean mass in Phase 2 trials.

Standard Dosing

Research indicates 10-25 mg daily orally for 8-12 weeks. Phase 2 clinical trials used 1-3 mg/day with significant lean mass gains.

Timing

Once daily, morning or evening. Consistent timing. Half-life approximately 24 hours. No food timing requirements.

Cycle Duration

8-12 week cycles. PCT may be required depending on suppression level and cycle length.

Side Effects

• Testosterone suppression (dose and duration dependent — mild to moderate)
• Elevated liver enzymes (hepatotoxicity reports)
• HDL suppression
• Headache
• Nausea
• Back pain
• Joint dryness (from estradiol reduction secondary to testosterone suppression)

Contraindications

• Androgen-sensitive cancers (prostate, breast)
• Pre-existing liver disease
• Pregnancy and breastfeeding
• Individuals under 21 (potential endocrine development disruption)
• Athletes subject to WADA testing (prohibited substance)

Best Stacking Partners